Eletriptan
Relpax (eletriptan) is a small molecule pharmaceutical. Eletriptan was first approved as Relpax on 2002-12-26. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1A and 5-hydroxytryptamine receptor 1E.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Trade Name
FDA
EMA
Relpax (generic drugs available since 2017-06-16)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eletriptan hydrobromide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RELPAX | Upjohn | N-021016 RX | 2002-12-26 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
eletriptan | NDA authorized generic | 2021-07-08 |
relpax | New Drug Application | 2020-04-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ELETRIPTAN |
INN | eletriptan |
Description | Eletriptan is an N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group. It has a role as a serotonergic agonist, a vasoconstrictor agent and a non-steroidal anti-inflammatory drug. It is a member of indoles, a N-alkylpyrrolidine and a sulfone. It is a conjugate base of an eletriptan(1+). |
Classification | Small molecule |
Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12 |
Identifiers
PDB | — |
CAS-ID | 143322-58-1 |
RxCUI | 231049 |
ChEMBL ID | CHEMBL1510 |
ChEBI ID | 50922 |
PubChem CID | 77993 |
DrugBank | DB00216 |
UNII ID | 22QOO9B8KI (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1F
HTR1F
HTR1B
HTR1B
HTR1D
HTR1D
Alternate
HTR1A
HTR1A
HTR1E
HTR1E
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
Clinical Variant
No data
Financial
Relpax - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 603 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more